

Daniel F Alonso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2682637/publications.pdf>

Version: 2024-02-01

120
papers

3,305
citations

136950

32
h-index

182427

51
g-index

120
all docs

120
docs citations

120
times ranked

3345
citing authors

#	ARTICLE	IF	CITATIONS
1	Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. <i>FEBS Journal</i> , 1999, 263, 295-304.	0.2	170
2	Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2). <i>Cancer Research</i> , 2004, 64, 7127-7129.	0.9	139
3	Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 83-93.	2.5	135
4	Telomere structure and telomerase in health and disease. <i>International Journal of Oncology</i> , 2012, 41, 1561-1569.	3.3	126
5	Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. <i>Oncology Reports</i> , 2006, 16, 885-91.	2.6	109
6	CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in <i>Ávitro</i> and in <i>Ávivo</i> . <i>Molecular and Cellular Biochemistry</i> , 2008, 316, 163-167.	3.1	86
7	Active immunotherapy with 1E10 anti-idiotypic vaccine in patients with small cell lung cancer: Report of a phase I trial. <i>Cancer Biology and Therapy</i> , 2007, 6, 145-150.	3.4	75
8	NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-8.	3.3	67
9	Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 840-851.	1.7	67
10	Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. <i>EClinicalMedicine</i> , 2021, 37, 100959.	7.1	66
11	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. <i>International Journal of Cancer</i> , 2008, 122, 57-62.	5.1	64
12	Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. <i>BMC Cancer</i> , 2009, 9, 146.	2.6	64
13	1E10 anti-idiotypic vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients.. <i>Cancer Biology and Therapy</i> , 2007, 6, 1847-1852.	3.4	63
14	Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1189-1196.	4.1	62
15	Cancer vaccines: an update with special focus on ganglioside antigens. <i>Oncology Reports</i> , 2002, 9, 267-76.	2.6	60
16	Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 209-223.	2.5	58
17	Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 551-560.	3.3	58
18	The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipoxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target. <i>PLoS ONE</i> , 2012, 7, e40794.	2.5	51

#	ARTICLE	IF	CITATIONS
19	Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. <i>Journal of Surgical Oncology</i> , 1996, 62, 288-297.	1.7	47
20	Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-6.	3.3	45
21	AZT as a telomerase inhibitor. <i>Frontiers in Oncology</i> , 2012, 2, 113.	2.8	45
22	T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1701-1710.	4.2	43
23	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 45-50.	3.1	41
24	Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine. <i>Journal of Immunotherapy</i> , 2004, 27, 442-451.	2.4	39
25	Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain. <i>Cancer Research</i> , 2003, 63, 2284-91.	0.9	39
26	Detection and Characterization of N-Glycolyated Gangliosides in Wilms Tumor by Immunohistochemistry. <i>Pediatric and Developmental Pathology</i> , 2010, 13, 18-23.	1.0	38
27	Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. , 1996, 65, 812-820.		37
28	Chronic In Vitro Exposure to 3-azido-2,3-dideoxythymidine Induces Senescence and Apoptosis and Reduces Tumorigenicity of Metastatic Mouse Mammary Tumor Cells. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 93-99.	2.5	36
29	Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. <i>Journal of Surgical Oncology</i> , 2002, 81, 38-44.	1.7	36
30	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	4.4	35
31	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 9-18.	2.5	34
32	A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. <i>SpringerPlus</i> , 2015, 4, 428.	1.2	34
33	A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2120-2124.	1.5	34
34	Antimetastatic effect of desmopressin in a mouse mammary tumor model. <i>Breast Cancer Research and Treatment</i> , 1999, 57, 271-275.	2.5	32
35	Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. <i>Veterinary Journal</i> , 2008, 178, 103-108.	1.7	32
36	Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 153-162.	3.1	32

#	ARTICLE	IF	CITATIONS
37	Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and its Relation to Histologic Grade. <i>Journal of the American Animal Hospital Association</i> , 2011, 47, 21-27.	1.1	32
38	Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. <i>ISRN Gastroenterology</i> , 2011, 2011, 1-8.	1.5	32
39	Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. <i>British Journal of Cancer</i> , 2015, 112, 1636-1643.	6.4	32
40	Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. <i>Cellular Signalling</i> , 2017, 30, 154-161.	3.6	32
41	Combined therapeutic effect of a monoclonal anti-idiotypic tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 379-389.	2.5	31
42	Ganglioside-based vaccines and anti-idiotypic antibodies for active immunotherapy against cancer. <i>Expert Review of Vaccines</i> , 2003, 2, 817-823.	4.4	30
43	Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. <i>Frontiers in Oncology</i> , 2012, 2, 150.	2.8	30
44	CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. <i>Lung Cancer</i> , 2017, 107, 14-21.	2.0	30
45	Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. <i>Future Medicinal Chemistry</i> , 2011, 3, 1987-1993.	2.3	28
46	Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. <i>Journal of Peptide Science</i> , 2012, 18, 215-223.	1.4	28
47	The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. <i>International Journal of Oncology</i> , 2015, 46, 2335-2345.	3.3	28
48	Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. <i>JAMA Ophthalmology</i> , 2015, 133, 805.	2.5	28
49	A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. <i>Melanoma Research</i> , 2001, 11, 219-227.	1.2	27
50	7A7 MAb: A New Tool for the Pre-Clinical Evaluation of EGFR-Based Therapies. <i>Hybridoma</i> , 2004, 23, 168-175.	0.4	26
51	Proteomic Profile Regulated by the Anticancer Peptide CIGB-300 in Non-Small Cell Lung Cancer (NSCLC) Cells. <i>Journal of Proteome Research</i> , 2010, 9, 5473-5483.	3.7	26
52	Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. <i>European Journal of Cancer</i> , 2013, 49, 2892-2899.	2.8	26
53	Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. <i>OncoTargets and Therapy</i> , 2014, 7, 2021.	2.0	26
54	Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells. <i>Frontiers in Oncology</i> , 2017, 7, 11.	2.8	24

#	ARTICLE	IF	CITATIONS
55	Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model. <i>Clinical Cancer Research</i> , 2006, 12, 7092-7098.	7.0	21
56	Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. <i>JAMA Ophthalmology</i> , 2016, 134, 1374.	2.5	21
57	Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1285-1296.	4.2	21
58	A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and β 21-integrin point contact distribution. , 1997, 71, 881-890.		20
59	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. <i>Experimental Cell Research</i> , 2011, 317, 1677-1688.	2.6	20
60	Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. <i>Cancer Letters</i> , 1993, 70, 181-187.	7.2	19
61	Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 146.	8.6	18
62	Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines. <i>Molecular Pharmaceutics</i> , 2014, 11, 1798-1807.	4.6	18
63	Racotumomab for treating lung cancer and pediatric refractory malignancies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 573-578.	3.1	18
64	<i>In vitro</i> and <i>in vivo</i> antitumor activity of Yerba Mate extract in colon cancer models. <i>Journal of Food Science</i> , 2020, 85, 2186-2197.	3.1	18
65	Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. <i>Molecular Medicine Reports</i> , 2010, 3, 253-9.	2.4	18
66	Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTX83 and the Originator Rituximab. <i>BioDrugs</i> , 2016, 30, 225-231.	4.6	17
67	Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. <i>Frontiers in Oncology</i> , 2012, 2, 160.	2.8	16
68	Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. <i>Anticancer Research</i> , 2008, 28, 2607-11.	1.1	16
69	Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. <i>Anticancer Research</i> , 2010, 30, 5049-54.	1.1	16
70	Preclinical Efficacy of [V4 Q5]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 438-450.	3.0	15
71	Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 51-56.	3.3	14
72	Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1356, 171-184.	4.1	14

#	ARTICLE	IF	CITATIONS
73	RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging. <i>Cell Death and Disease</i> , 2015, 6, e1902-e1902.	6.3	14
74	Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. <i>In Vivo</i> , 2012, 26, 609-17.	1.3	14
75	Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. <i>Molecular Medicine Reports</i> , 2014, 9, 2568-2572.	2.4	13
76	Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. <i>Anticancer Research</i> , 2014, 34, 4761-5.	1.1	13
77	Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 589-600.	3.3	12
78	Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastatic colonization. <i>Scientific Reports</i> , 2020, 10, 14689.	3.3	12
79	States of stability/lysis in human fetal and adults red blood cells. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1989, 97, 309-316.	0.2	11
80	Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia. <i>Journal of the Neurological Sciences</i> , 1996, 139, 83-88.	0.6	11
81	Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: Enhancement by paclitaxel and inhibition by nocodazole. , 1999, 83, 242-246.		11
82	Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells. , 1998, 76, 362-367.		10
83	Role of Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor in Mice Bearing a Highly Invasive and Metastatic Mammary Carcinoma. <i>Pathobiology</i> , 1999, 67, 180-185.	3.8	10
84	Cancer Antigen Prioritization: A Road Map to Work in Defining Vaccines Against Specific Targets. A Point of View. <i>Frontiers in Oncology</i> , 2012, 2, 66.	2.8	9
85	Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 669-677.	2.5	8
86	Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. <i>Viruses</i> , 2021, 13, 2084.	3.3	8
87	Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing β 2-chimaerin. <i>Molecular Medicine Reports</i> , 2008, 2, 97-102.	2.4	7
88	Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106125.	2.5	7
89	Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 566.	1.8	7
90	Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. <i>In Vivo</i> , 2006, 20, 881-5.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Effect of Host-Organ Environment on the in vivo and in vitro Behavior of a Murine Mammary Adenocarcinoma. <i>Tumor Biology</i> , 1994, 15, 284-293.	1.8	6
92	Tissue factor as a novel marker for detection of circulating cancer cells. <i>Biomarkers</i> , 2011, 16, 58-64.	1.9	6
93	Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1490.	2.8	6
94	In Vitro Activity of a Solanum tuberosum Extract against Mammary Carcinoma Cells. <i>Planta Medica</i> , 2001, 67, 164-166.	1.3	5
95	Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 597-599.	2.5	5
96	Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches. <i>Future Medicinal Chemistry</i> , 2018, 10, 879-894.	2.3	5
97	Implication of von Willebrand Factor as a Regulator of Tumor Cell Metastasis: Potential Perioperative Use of Desmopressin and Novel Peptide Analogs. <i>Acta Haematologica</i> , 2013, 129, 223-224.	1.4	4
98	<i>In vitro</i> and <i>in vivo</i> evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment. <i>Nanomedicine</i> , 2018, 13, 2835-2849.	3.3	4
99	Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma. <i>British Journal of Ophthalmology</i> , 2018, 102, 1597-1601.	3.9	4
100	Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent. <i>Vitamins and Hormones</i> , 2020, 113, 259-289.	1.7	4
101	Aberrant O-glycosylation modulates aggressiveness in neuroblastoma. <i>Oncotarget</i> , 2018, 9, 34176-34188.	1.8	4
102	Desmopressin and other synthetic vasopressin analogues in cancer treatment. <i>Bulletin Du Cancer</i> , 2006, 93, E7-12.	1.6	4
103	Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotypic antibody targeting NeuGcGM3. <i>Frontiers in Immunology</i> , 2012, 3, 422.	4.8	3
104	Minimally disseminated disease and outcome in overt orbital retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27662.	1.5	3
105	Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial. <i>Investigational New Drugs</i> , 2020, 38, 1580-1587.	2.6	3
106	Anti-idiotypic antibodies in cancer treatment. <i>Frontiers in Oncology</i> , 2013, 3, 37.	2.8	2
107	Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells – Letter. <i>Cancer Research</i> , 2016, 76, 4908-4908.	0.9	2
108	Impact of Perioperative Blood Transfusion on Survival Among Women With Breast Cancer: Potential Benefits of Blood-Saving Agent Desmopressin Use During Surgery. <i>American Journal of Therapeutics</i> , 2018, 25, e569-e570.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Potential Use of Desmopressin During Hepatic Resection for Colorectal Liver Metastases*. Journal of Surgical Research, 2019, 237, 1-2.	1.6	2
110	CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy. , 2015, , 281-298.		2
111	Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Research, 2004, 24, 1737-43.	1.1	2
112	Role of beta2-chimaerin in the behaviour of murine mammary carcinoma cells in response to extracellular matrix components. International Journal of Molecular Medicine, 2005, 15, 91-5.	4.0	2
113	Molecular detection of circulating tyrosinase mRNA: optimization in a preclinical xenograft mouse melanoma model and further evaluation in samples from advanced melanoma patients. International Journal of Molecular Medicine, 2008, 21, 555-9.	4.0	2
114	Function and Expression of the uPA/uPAR System in Cancer Metastasis. , 0, , 223-236.		1
115	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates. Journal of Gastrointestinal Surgery, 2017, 21, 1971-1973.	1.7	1
116	Desmopressin in canine mammary carcinoma: Comments on the importance of the administration route. Veterinary and Comparative Oncology, 2021, 19, 409-410.	1.8	1
117	Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. , 1996, 62, 288.		1
118	Effect of atorvastatin in a case of feline multicentric lymphoma " Case report. Acta Veterinaria Hungarica, 2011, 59, 69-76.	0.5	0
119	Re: Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor. Journal of the National Cancer Institute, 2012, 104, 1917-1917.	6.3	0
120	Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver. Eurasian Journal of Medicine, 2015, 47, 229-230.	0.6	0